FY2027 EPS Estimates for Envista Lowered by Leerink Partnrs

Envista Holdings Co. (NYSE:NVST - Free Report) - Equities researchers at Leerink Partnrs cut their FY2027 earnings per share (EPS) estimates for Envista in a research note issued to investors on Wednesday, April 9th. Leerink Partnrs analyst M. Cherny now forecasts that the company will earn $1.28 per share for the year, down from their previous forecast of $1.45. The consensus estimate for Envista's current full-year earnings is $1.00 per share.

Envista (NYSE:NVST - Get Free Report) last posted its quarterly earnings data on Wednesday, February 5th. The company reported $0.24 EPS for the quarter, beating analysts' consensus estimates of $0.23 by $0.01. Envista had a negative net margin of 44.56% and a positive return on equity of 3.86%.

Other equities research analysts have also issued research reports about the company. Morgan Stanley set a $16.00 target price on Envista in a research report on Tuesday. New Street Research set a $19.00 price target on Envista in a report on Thursday, March 6th. Wells Fargo & Company set a $19.00 price objective on shares of Envista in a research note on Saturday, March 8th. UBS Group cut their target price on shares of Envista from $23.00 to $21.00 and set a "neutral" rating on the stock in a research note on Monday, March 10th. Finally, JPMorgan Chase & Co. decreased their price target on shares of Envista from $20.00 to $19.00 and set a "neutral" rating for the company in a research note on Thursday, March 6th. Two analysts have rated the stock with a sell rating, ten have given a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, Envista currently has a consensus rating of "Hold" and an average price target of $19.96.

Envista Trading Up 1.1 %

NVST traded up $0.17 during trading on Monday, reaching $15.19. 2,104,731 shares of the stock traded hands, compared to its average volume of 2,486,019. The stock's 50-day moving average is $17.82 and its 200 day moving average is $19.21. Envista has a 12 month low of $14.22 and a 12 month high of $23.00. The company has a quick ratio of 1.76, a current ratio of 2.04 and a debt-to-equity ratio of 0.44. The stock has a market capitalization of $2.62 billion, a PE ratio of -2.34, a P/E/G ratio of 1.27 and a beta of 1.12.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of NVST. Palouse Capital Management Inc. raised its position in Envista by 14.4% in the 1st quarter. Palouse Capital Management Inc. now owns 9,444 shares of the company's stock valued at $163,000 after buying an additional 1,186 shares during the last quarter. Wealth Enhancement Advisory Services LLC raised its holdings in shares of Envista by 220.5% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 47,319 shares of the company's stock valued at $817,000 after purchasing an additional 32,556 shares during the last quarter. SG Americas Securities LLC lifted its position in shares of Envista by 594.3% during the first quarter. SG Americas Securities LLC now owns 108,509 shares of the company's stock valued at $1,873,000 after purchasing an additional 92,880 shares in the last quarter. UMB Bank n.a. boosted its holdings in Envista by 214.4% during the first quarter. UMB Bank n.a. now owns 2,094 shares of the company's stock worth $36,000 after purchasing an additional 1,428 shares during the last quarter. Finally, GAMMA Investing LLC grew its position in Envista by 1,338.3% in the 1st quarter. GAMMA Investing LLC now owns 33,139 shares of the company's stock worth $572,000 after purchasing an additional 30,835 shares in the last quarter.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.